Xianhua Mao

Xianhua Mao

Auto-generated profile, based on publicly available information

Xianhua Mao

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JFJiahui Fan
Jiahui Fan
ZLZhenqiu Liu
Zhenqiu Liu
XMXianhua Mao
Xianhua Mao
XTXin Tong
Xin Tong
TZTiejun Zhang
Tiejun Zhang
XCXingdong Chen
Xingdong Chen
Background: The incidence and mortality of esophageal cancer are high, with 5.90 new cases and 5.48 deaths per 100 000 people worldwide in 2017. The prognosis of esophageal cancer is poor, with an overall 5‐year survival rate of less than 20%. Esophageal cancer in different geographical locations has different etiologies, and the incidence and mortality of esophageal cancer continue to rise in some regions.Methods: We collected incidence and mortality data by age and gender for 195 countries and territories from 1990 to 2017 in the Global Burden of Disease (GBD) database. And we used these data to calculate the estimated annual percentage change (EAPC) to quantify trends in morbidity and mortality. Then we analyzed the gender‐ and age‐specific incidence and mortality in esophageal cancer to targeted high‐risk populations. Finally, we analyzed the correlation between the age‐standardized mortality rate (ASMR) and both the EAPC and social‐demographic index (SDI), and we calculated the Pearson correlation coefficient.Results: We found that Malawi, East Asia, and high‐middle SDI regions had the highest age‐standardized incidence rate (ASIR) and ASMR, and the ASIR and ASMR in western Sub‐Saharan Africa showed an upward trend. Our study also showed that the incidence and mortality in esophageal cancer were highest in men and in the 70+ years age group, and they presented a decreasing trend in most regions, but the 15‐49 years age groups in Australasia, Caribbean, and Oceania and the 70+ years age group in High‐Income North America, Oceania and high‐SDI regions presented an increasing trend. There were significant negative associations between ASMR at baseline and EAPC and between ASMR and SDI in 2017.Conclusion: By analyzing the global distribution of incidence and mortality in esophageal cancer, trends over time, and gender and age specificity, we can understand the heterogeneity of its global trends. This heterogeneity can help us to identify high‐risk groupsand to provide clues for the exploration of the etiology and early prevention of the disease.

23 March 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
ZLZhenqiu Liu
Zhenqiu Liu
CSChen Suo
Chen Suo
XMXianhua Mao
Xianhua Mao
YJYanfeng Jiang
Yanfeng Jiang
LJLi Jin
Li Jin
XCXingdong Chen
Xingdong Chen

6 August 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ZLZhenqiu Liu
Zhenqiu Liu
XMXianhua Mao
Xianhua Mao
YJYanfeng Jiang
Yanfeng Jiang
NCNing Cai
Ning Cai
LJLi Jin
Li Jin
XCXingdong Chen
Xingdong Chen
Background: Liver cancer is a commonly diagnosed malignancy in China. The etiologies of liver cancer are widely known, although studies on temporal trends in liver cancer caused by specific etiologies are rare.Methods: Data on the incidence and mortality of liver cancer were retrieved from the Global Burden of Diseases Study 2017. The estimated annual percentage change (EAPC) was used to quantify temporal trends in the age‐standardized incidence rate (ASIR) and the age‐standardized mortality rate (ASMR) of liver cancer from 1990 to 2017.Results: Nationwide, the number of incident cases of liver cancer increased from 258 000 in 1990 to 515 900 in 2017. The ASIR decreased from 27.16 per 100 000 to 26.04 per 100 000 during this period, with an EAPC of −0.64 (95% confidence interval [CI] −0.84, −0.44). The number of deaths increased from 245 300 in 1990 to 418 200 in 2017, and the ASMR decreased from 26.72 to 21.30 (EAPC = −1.16, 95% CI −1.35, −0.97). The most pronounced decreases in the ASIR and ASMR were observed in liver cancer due to hepatitis B and in people aged 15‐49 years.Conclusions: Since the extensive efforts for prevention of hepatitis B virus infection, the incidence of liver cancer due to hepatitis B has significantly decreased. However, liver cancer due to hepatitis C, NASH, and other causes remains a major public health concern. Additional preventive strategies tailored to liver cancer are needed to further reduce its disease burden in China.

9 July 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
XMXianhua Mao
Xianhua Mao
XZXinrong Zhang
Xinrong Zhang
LHLinda Henry
Linda Henry
KCKa Shing Cheung
Ka Shing Cheung
MYMan-Fung Yuen
Man-Fung Yuen
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Background: Evidence regarding the effect of glucagon-like peptide 1 receptor (GLP-1) agonist, when compared with other glucose-lowering drugs, on obesity-related cancer in overweight or obese patients with type 2 diabetes is limited. Methods: Using Merative Marketscan research databases, we identified all overweight or obese patients with type 2 diabetes aged 20-79 years who received GLP-1 agonist or other glucose-lowering drugs in the United States between January 2016 and June 2021. The primary outcome was obesity-related cancer, defined as a component of 13 cancer types. Results: Among 919 609 overweight or obese individuals with type 2 diabetes (mean [SD] age = 52.3 [10.9] years; female, 53.5%), 16 653 newly diagnosed with obesity-related cancer were recorded during the 2 086 526 person-years of follow-up. GLP-1 agonist users (vs other glucose-lowering drugs users) were associated with lower incidence (7.5 vs 8.1 per 1000 person-years) and risk of obesity-related cancer (adjusted hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.83 to 0.91). This statistically significant association was consistent when comparing GLP-1 agonist with metformin (adjusted HR = 0.90, 95% CI = 0.86 to 0.95), dipeptidyl peptidase-4 inhibitor (adjusted HR = 0.88, 95% CI = 0.84 to 0.93), thiazolidinediones (adjusted HR = 0.84, 95% CI = 0.71 to 0.99), sulfonylureas (adjusted HR = 0.81, 95% CI = 0.74 to 0.88), sodium-glucose transport protein 2 inhibitor (adjusted HR = 0.73, 95% CI = 0.66 to 0.80), and insulin (adjusted HR = 0.70, 95% CI = 0.65 to 0.76; all P < .05) and was strengthened with increasing weight (overweight, mild to moderate, and severe obesity: HR = 0.95, 95% CI = 0.81 to 1.10, vs HR = 0.90, 95% CI = 0.84 to 0.97, vs HR = 0.82, 95% CI = 0.77 to 0.88, respectively; Pinteraction = .032). Conclusions: In a nationwide US cohort of overweight or obese patients with type 2 diabetes, GLP-1 agonist, when compared with other glucose-lowering drugs, was associated with a lower risk of obesity-related cancer, with more pronounced risk reduction with increasing body weight.

24 April 2025 in Cancer Communications
Verified
Journal Article
Open access
XMXianhua Mao
Xianhua Mao
KCKa Shing Cheung
Ka Shing Cheung
JTJing‐Tong Tan
Jing‐Tong Tan
LMLung‐Yi Mak
Lung‐Yi Mak
CLChi‐Ho Lee
Chi‐Ho Lee
WSWai‐Kay Seto
Wai‐Kay Seto

23 April 2026 in Hepatology
Verified
Journal Article
Closed access
XMXianhua Mao
Xianhua Mao
HFHong Fan
Hong Fan
MYMan-Fung Yuen
Man-Fung Yuen
RCRamsey Cheung
Ramsey Cheung
WSWai-Kay Seto
Wai-Kay Seto
MNMindie H. Nguyen
Mindie H. Nguyen
Background and Aims: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors individually benefit patients with metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to evaluate the effect of GLP-1 receptor agonist–SGLT-2 inhibitor combination on the risk of major adverse liver and cardiovascular outcomes compared with either agent alone among patients with MASLD and type 2 diabetes (T2D). Approach and Results: This is a target trial emulation study using data from U.S. MarketScan databases. Propensity score–matched cohorts were built to compare (1) 4606 patients who received GLP-1 receptor agonist–SGLT-2 inhibitor combination with 18,424 who received only GLP-1 receptor agonist, and (2) 5368 patients who received this combination with 21,472 who received only SGLT-2 inhibitors. Cox regression models were conducted in on-treatment designs. Compared with GLP-1 receptor agonists, the GLP-1 receptor agonist–SGLT-2 inhibitor combination was associated with a 39% lower risk of major adverse liver outcomes [HR 0.61 (95% CI 0.49–0.77)] and a 35% lower risk of major adverse cardiovascular events [HR 0.65 (0.60–0.70)] during a median follow-up of 6.3 months. Compared with SGLT-2 inhibitors, the combination was associated with a 43% lower risk of major adverse liver outcomes [HR 0.57 (0.46–0.69)] and a 20% lower risk of major adverse cardiovascular events [HR 0.80 (0.75–0.86)] during a median follow-up of 6.0 months. Conclusions: In this study, the GLP-1 receptor agonist–SGLT-2 inhibitor combination was associated with a lower risk of major adverse liver and cardiovascular outcomes compared with either agent alone among patients with MASLD and T2D.